Itoh Hiroki, Nagano Toshiaki, Takeyama Masaharu
Department of Clinical Pharmacy, Oita Medical University, Japan.
J Pharm Pharmacol. 2002 Jun;54(6):869-73. doi: 10.1211/0022357021779050.
The effect of the histamine H2-receptor antagonist, nizatidine, on plasma concentrations of paracetamol has been investigated with respectto hepatic metabolism. Paracetamol (1000 mg) together with 300 or 150 mg nizatidine or placebo was orally administered to five healthy male volunteers. Venous blood samples were taken before and after administration. Plasma paracetamol and paracetamol conjugates (glucuronide and sulfate) were measured by high-performance liquid chromatography. The pharmacokinetic parameters were calculated from the plasma paracetamol concentration-time curves of each volunteer. The plasma nizatidine concentration was highest (2420.0+/-192.4 and 996.0+/-54.6 ng mL(-1)) in the sample taken 1 h after administration of 300 mg nizatidine (high dose) and 150mg nizatidine (low dose), respectively. Plasma paracetamol concentrations with nizatidine (high and low doses) were increased significantly at 45-120 min and 45-60 min, respectively, compared with placebo. The total area under the plasma paracetamol concentration-time curve from 0 to 180 min (2361.5+/-146.4 and 2085.75+/-73.5 microg min mL(-1)) significantly increased after coadministration of nizatidine (high and low doses), respectively (P < 0.01 vs placebo). Paracetamol glucuronide concentrations with nizatidine (high and low doses) were decreased significantly at 30-45 min and 30 min, respectively, compared with placebo. However, plasma paracetamol sulfate concentrations with nizatidine (high and low doses) were not significantly altered. The coadministration of nizatidine (150 and 300 mg) dose-dependently reduces plasma paracetamol glucuronide concentrations and increases plasma paracetamol concentrations. The effects of nizatidine could result from the inhibition of glucuronyltransferase. Thus, care is necessary when paracetamol and nizatidine are coadministered.
已针对肝脏代谢研究了组胺H2受体拮抗剂尼扎替丁对扑热息痛血浆浓度的影响。将扑热息痛(1000毫克)与300毫克或150毫克尼扎替丁或安慰剂一起口服给予5名健康男性志愿者。给药前后采集静脉血样。通过高效液相色谱法测定血浆扑热息痛和扑热息痛结合物(葡萄糖醛酸苷和硫酸盐)。根据每位志愿者的血浆扑热息痛浓度-时间曲线计算药代动力学参数。分别在给予300毫克尼扎替丁(高剂量)和150毫克尼扎替丁(低剂量)后1小时采集的样本中,血浆尼扎替丁浓度最高(分别为2420.0±192.4和996.0±54.6纳克/毫升)。与安慰剂相比,尼扎替丁(高剂量和低剂量)组的血浆扑热息痛浓度分别在45 - 120分钟和45 - 60分钟时显著升高。尼扎替丁(高剂量和低剂量)共同给药后,0至180分钟血浆扑热息痛浓度-时间曲线下的总面积(分别为2361.5±146.4和2085.75±73.5微克·分钟/毫升)显著增加(与安慰剂相比,P < 0.01)。与安慰剂相比,尼扎替丁(高剂量和低剂量)组的扑热息痛葡萄糖醛酸苷浓度分别在30 - 45分钟和30分钟时显著降低。然而,尼扎替丁(高剂量和低剂量)组的血浆扑热息痛硫酸盐浓度没有显著改变。尼扎替丁(150毫克和300毫克)共同给药剂量依赖性地降低血浆扑热息痛葡萄糖醛酸苷浓度并增加血浆扑热息痛浓度。尼扎替丁的作用可能是由于抑制了葡萄糖醛酸转移酶。因此,扑热息痛和尼扎替丁共同给药时需要谨慎。